Effect of R115777 on Breast Cancer Growth
Author Information
Author(s): Fredrik Wärnberg, Daniel White, Elizabeth Anderson, Fiona Knox, Robert B Clarke, Julie Morris, Nigel J Bundred
Primary Institution: Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
Hypothesis
The study investigates the effects of the farnesyl transferase inhibitor R115777 on breast cancer cell growth and ductal carcinoma in situ (DCIS) in a xenograft model.
Conclusion
R115777 treatment reduced cell growth in vitro and tumor growth in vivo, indicating its potential as a breast cancer treatment.
Supporting Evidence
- R115777 reduced cell growth in vitro and tumor growth in vivo.
- Treatment resulted in a decreased cell turnover index in DCIS xenografts.
- Significant tumor growth inhibition was observed in MCF-7/HER2-18 cell line tumors.
Takeaway
This study tested a new drug that helps stop breast cancer cells from growing, and it worked in lab tests and in mice.
Methodology
The study involved in vitro tests on cancer cell lines and in vivo tests using a xenograft model with human DCIS implanted in mice.
Potential Biases
Potential bias due to the selection of cell lines and the lack of randomization in animal studies.
Limitations
The study did not assess the ras status of the DCIS lesions and had a small sample size for some analyses.
Participant Demographics
Women aged 39 to 72 with confirmed DCIS, with 9 out of 10 having foci of invasive cancer.
Statistical Information
P-Value
0.005
Confidence Interval
95%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website